Survey Finds Strong Interest in Hypothetical Dementia Vaccine Among Older Adults
A survey of Americans aged 50 and older found that 72.1% would likely or definitely accept a vaccine that could cut dementia risk by half if they were at high risk. Women and Black adults showed greater hesitation than men and white adults. No preventive dementia vaccine is approved, but existing shingles vaccines have been linked to lower dementia risk in observational studies.
The survey drew from the Understanding America Study, a nationally representative internet panel, with 1,529 respondents averaging 65.6 years old. The hypothetical scenario described a low-cost, multidose vaccine halving dementia risk for high-risk individuals. Notably, respondents with personal dementia exposure—either their own diagnosis or someone close—showed greater willingness, as did those with higher incomes and college degrees.
While no preventive dementia vaccine exists, observational research has linked shingles vaccination to reduced dementia risk. A Welsh natural experiment found the discontinued Zostavax shot associated with 20% lower risk, while Medicare data showed Shingrix linked to 33% lower risk. Some researchers speculate the AS01 adjuvant in certain vaccines may stimulate immune responses relevant to dementia prevention.
This survey signals that public appetite for dementia prevention may outpace scientific availability. If vaccine candidates reach trials or approval, disparities in acceptance—particularly among women and Black adults, groups facing higher dementia burdens—could widen existing health gaps. Outreach tailored to hesitant communities may become essential. Conversely, strong overall interest could accelerate research funding and clinical trial enrollment, potentially hastening the arrival of a first-generation preventive vaccine. The findings also suggest policymakers may need to plan for equitable distribution and cost considerations as these products move through development.